Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy
Clinical trial NCT02852837 · COMPLETED
Trial details
- NCT number
- NCT02852837
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-09-26
- Primary completion
- 2019-12-13
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.